Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AssigneeAngiochem Inc.
InventorsJean-Paul Castaigne, Michel Demeule, Betty Lawrence
Life of this patent
Estimating the term…
Abstract
Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an amino acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2.
Claims16
A method of treating a patient having metastatic ovarian cancer after failure of a prior chemotherapy that comprised a taxane, said method comprising administering to said patient an effective amount of ANG1005 which has the structure:
Dependencies are inferred from the claim text.